ClinicalTrials.gg
Status unknownNCT03291002Updated Nov 4, 2021

Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

A Phase 1 interventional study of CV8102 and CV8102 + anti-PD-1 therapy in Melanoma (Skin), Squamous Cell Carcinoma of the Skin and Carcinoma, Squamous Cell of Head and Neck, sponsored by CureVac. Status unknown at 22 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-04.

Sponsored by CureVac (part of BioNTech SE) · Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 284 studies in Melanoma with a site in Germany — 37 open to participants now, 70 under way, 20 of them phase 3. Melanoma · Germany.

Enrollment
151st of 249
98 · median 162
Started
2017
with 12 others
Phase 1
36 of 284
2 open now
Registered
175th of 284
by date

Among the 284 studies in Melanoma with a site in Germany, this one is the 151st largest by enrollment of the 249 interventional ones that give a count, is one of 13 that started in 2017, is one of 36 in phase 1, and was the 175th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

37 of the 284 studies in Melanoma with a site in Germany are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Melanoma with a site in Germany, or all of them as a file.
02

Study summary

This study evaluates intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.

Patients will receive CV8102 as single agent or in combination with SoC anti-PD-1 therapy.

03

Conditions studied

  • Melanoma (Skin)
  • Squamous Cell Carcinoma of the Skin
  • Carcinoma, Squamous Cell of Head and Neck
  • Carcinoma, Adenoid Cystic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Patients enrolled into Cohorts A and B (single agent CV8102) must have:

    • confirmed advanced cutaneous melanoma, cutaneous squamous cell carcinoma, head and neck squamous cell carcinoma, or adenoid cystic carcinoma with documented disease progression
    • not amenable to surgical resection or locoregional radiation therapy with curative intent
    • at least 1 line of anti-cancer therapy for advanced disease (except adenoid cystic carcinoma) and documented Progression
    • cutaneous melanoma Cohort B3: Willing to undergo baseline and post-baseline of the lesion which is to be injected
  2. Patients enrolled into Cohort C (CV8102 in combination with therapy) must have

    • histologically confirmed advanced cMEL or hnSCC
    • indication for anti-PD-1 therapy or currently receiving anti-PD-1 therapy with stable of slowly progressing disease after at last 8 weeks (hnSCC) or 12 weeks (cMEL) of anti-PD-1 therapy prior to Day 1
  3. Patients enrolled into Cohort D1 (CV8102 in combination with anti-PD-1 therapy) must have

    • histologically confirmed advanced cMEL
    • either anti-PD-1 naive patients with indication for anti-PD-1 therapy (Cohort D1a) or patients to anti-PD-1 therapy (Cohort D1b)
    • Presence of (s) according to 1.1, not intended for injection
    • Willing to undergo tumor biopsies at specific timepoints (Cohort D1a: baseline; Cohort D1b baseline and post-baseline biopsy of the injected lesion - only for selected sites)
  4. Patients enrolled into Cohort D2 (CV8102 in combination with anti-PD-1 therapy) must have

    • histologically confirmed advanced hnSCC
    • indication for treatment with pembrolizumab (patients naive to anti-PD-1/anti-PD-L1)
    • PD-L1 combined positive score ≥ 1% according to local practice
  5. Presence of at least one injectable tumor lesion that is measurable according to RECIST 1.1
  6. Recovered from prior toxicities to grade ≤ 1 or grade ≤ 2
  7. Resolution of CPI-related adverse effects, if applicable (including irAEs) back to CTCAE grade 0/1
  8. PS 0 or 1
  9. 18 years of age or older
  10. Adequate hematologic, renal, hepatic and coagulation function
  11. Use of effective

Key Exclusion Criteria:

  1. Rapidly progressing multi-focal or acutely life threatening disease
  2. Prior use of topical/localTLR-7/8 agonists within the past 6 months
  3. Clinically active central nervous system metastases and/or carcinomatous meningitis (patients with stable are eligible)
  4. Ocular and mucosal melanoma
  5. Prior anti-cancer therapy within specified time-periods depending on the indication
  6. Tumor lesions that are to be injected close to major blood vessels or nerves, or whose injection could potentially result in clinical adverse effects if post-treatment tumor swelling or inflammation were to occur
  7. Lesions that are to be injected in previously irradiated areas unless progressive tumor growth has been demonstrated (no prior irradiation of injected lesions on patients with melanoma)
  8. History of active coagulation or bleeding disorder or need for ongoing therapeutic anticoagulation that cannot be safely interrupted at th etime of IT injection or biopsy du eto Underlying medical conditions; patients with melanoma and cutaneous squamous cell carcinoma with controlled oral anticoagulation are eligible
  9. Treatment with any anticancer agent within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug or planned during the study
  10. Acute hypophysitis or endocrinopathies that are not adequately controlled by hormonal replacement therapy or thyreostatic treatment
  11. Use of immune modulating drugs or immunologically active topical therapies within 28 days of administration of the first dose of study drug
  12. Chronic systemic therapy including chronic within 28 days of the first dose of study drug (except physiological maintenance/replacement steroid doses, topical steroids outside the injected lesion or inhaled steroids); patients are eligible if steroid requirement is \< 10 mg/day of prednisone (or equivalent) for at least 2 weeks
  13. History of active disease requiring immunosuppressive medication (except Vitiligo and except CPI-mediated irAEs)
  14. Known hematologic or malignant primary solid tumor that have occured or reoccurred within the previous 5 years
  15. Recent thromboembolic complications, or cardiovascular disease, or any other uncontrolled illness that would pose a risk to patient safety
  16. Severe infection or acute inflammatory state
  17. Seropositivity for (HIV), virus (HBV) surface antigen (except in previously vaccinated patients) or virus (HCV)
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Cohort A

    Dose escalation of CV8102

    Biological: CV8102

  • Experimental
    Cohort B

    Optional expansion cohorts of CV8102

    Biological: CV8102

  • Experimental
    Cohort C

    Dose escalation of CV8102 + anti-PD-1 therapy

    Biological: CV8102 + anti-PD-1 therapy

  • Experimental
    Cohort D

    Optional expansion of CV8102 + anti-PD-1 therapy

    Biological: CV8102 + anti-PD-1 therapy

Interventions

  • BiologicalCV8102

    CV8102 alone

  • BiologicalCV8102 + anti-PD-1 therapy

    CV8102 in combination with standard of care anti-PD-1 therapy

06

What researchers measure

Primary outcomes

  1. Dose determination for dose escalation cohorts

    * Maximum tolerated dose (MTD) and recommended dose (RD), respectively, for CV8102 alone * MTD and recommended combination dose (RCD) for CV8102 in combination with the standard dose of an anti-PD-1 antagonist

    Time frame: 2 weeks

  2. Incidence of treatment related (Serious) Adverse Events (Tolerability and Safety profile)

    • Tolerability and safety profile of CV8102 alone and in combination with anti-PD-1 antagonists

    Time frame: up to 12 months (end of study)

Secondary outcomes

  1. Tumor response

    • Anti-tumor activity of CV8102 per irRECIST and RECIST 1.1

    Time frame: up to 12 months (end of study)

  2. Disease status

    • Tumor Assessment

    Time frame: 6 months

  3. Tumor response

    • Extent of tumor response at injected and non-injected lesions, if applicable

    Time frame: up to 12 months (end of study)

  4. Survival

    • Survival time

    Time frame: up to 12 months (end of study)

07

Study locations

22 sites
  • Medical University of Graz
    Graz, Austria
  • Universitätsklinik für Dermatologie der Paracelsus medizinischen Privatuniversität Salzburg
    Salzburg, Austria
  • Hôpital Saint Louis
    Paris, France
  • Institut Gustave Roussy
    Paris, France
  • Charité Benjamin Franklin
    Berlin, Germany
  • Medizinische Klinik III, Universitätsklinikum Bonn, Hämatologie, Immunonkologie und Rheumatologie
    Bonn, Germany
  • Elbe-Klinikum-Buxtehude, Hautkrebszentrum
    Buxtehude, Germany
  • Universitätsklinikum Erlangen,Hautklinik, Internistisches Zentrum (INZ)
    Erlangen, Germany
  • Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
    Heidelberg, Germany
  • Universitätsklinikum Schleswig-Holstein, Klinik für Dermatologie, Allergologie und Venerologie
    Lübeck, Germany
  • Fachklinik Hornheide
    Münster, Germany
  • Universitätsklinikum Münster, Klinik für Hautkrankheiten, ZiD- Zentrum für innovative Dermatologie
    Münster, Germany
  • Universitäts-Hautklinik, Abtl. Dermatologische Onkologie
    Tübingen, Germany
  • Center for Personalized Oncology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
    Moscow, Russian Federation
  • FSBI "National Medical Research Center of Oncology n.a. N.N. Blokhin" of the Ministry of Healthcare of the Russian Federation
    Moscow, Russian Federation
  • FSBI "National Medical Research Oncology Center n.a. N.N. Petrov
    Saint Petersburg, Russian Federation
  • Saint-Petersburg State University, Clinic of advanced medical technologies n. a. Nicolay I. Pirogov.
    Saint Petersburg, Russian Federation
  • Hospital Duran i Reynals - Institut Catala dOncologia ICO
    Barcelona, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Hospital Ramon y Cajal
    Madrid, Spain
  • Hospital Universitario Virgen de la Victoria
    Málaga, Spain
  • Hospital Universitario Marqus de Valdecilla Santander
    Santander, Spain
08

References and documents

Publications

  • Lutz J, Meister M, Habbeddine M, Fiedler K, Kowalczyk A, Heidenreich R. Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity. Cancer Immunol Immunother. 2023 May;72(5):1075-1087. doi: 10.1007/s00262-022-03311-4. Epub 2022 Nov 2. PubMed 36319717 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2017 (actual). Primary completion is estimated for Oct 2022, 61 months after the start.

Of 226 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's planned 61 months is above that.

Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2017
First posted
Sep 25, 2017
StartActual
Sep 25, 2017
Primary completionEst.
Oct 2022
CompletionEst.
Feb 2023
Last update
Nov 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03291002
Lead sponsor
CureVac
Collaborators
Syneos Health, Cromos Pharma LLC
Responsible party
Sponsor
First posted
Sep 25, 2017
Start date
Sep 25, 2017
Primary completion
Oct 2022 (estimated)
Completion
Feb 2023 (estimated)
Last update
Nov 4, 2021

Study contacts

Thomas Eigentler, Prof. Dr.
principal investigator · thomas.eigentler@charite.de

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CV-8102

Start the discussion